Berberine as a Modulator of Metabolic and Hormonal Dysregulation in PCOS: Mechanisms of Action and Clinical Implications - A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.55.70895Keywords
Polycystic ovary syndrome, PCOS, berberine, hyperandrogenism, insulin resistanceAbstract
Background. Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age and is a leading cause of anovulatory infertility. Its pathogenesis is considered multifactorial, involving polygenic susceptibility, environmental influences, and possible epigenetic modifications, although no definitive etiological trigger has been identified and no validated genetic screening is currently recommended. PCOS is associated with significantly reduced quality of life due to both metabolic and hyperandrogenic features, with diagnostic criteria remaining based on the Rotterdam framework.
Materials and methods. An extensive literature review was conducted using sources retrieved from the PubMed and Google Scholar databases.
Aim. The aim of this study was to analyze and synthesize the current body of evidence on polycystic ovary syndrome (PCOS), with a particular focus on evaluating the role of non-pharmacological interventions, especially berberine supplementation.
Conclusions. Berberine exhibits pleiotropic benefits in women with PCOS, improving insulin sensitivity, glycemic control, and lipid profiles through modulation of key metabolic pathways. It also demonstrates antiandrogenic effects by reducing free testosterone and increasing SHBG levels, contributing to improved hormonal balance and reproductive function. Overall, berberine appears to be a promising and well-tolerated adjunct or alternative therapy, although further high-quality studies are needed to confirm its long-term efficacy and impact on reproductive outcomes.
References
1. Dong, J., & Rees, D. A. (2023). Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ medicine, 2(1), e000548. https://doi.org/10.1136/bmjmed-2023-000548
2. Zhou, K., Zhang, J., Xu, L., & Lim, C. E. D. (2021). Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. The Cochrane database of systematic reviews, 6(6), CD007535. https://doi.org/10.1002/14651858.CD007535.pub4
3. Amisi C. A. (2022). Markers of insulin resistance in Polycystic ovary syndrome women: An update. World journal of diabetes, 13(3), 129–149. https://doi.org/10.4239/wjd.v13.i3.129
4. Neven, A. C. H., Forslund, M., Ranasinha, S., Sethi, P., Dhungana, R. R., Mousa, A., Tay, C. T., Teede, H., & Boyle, J. A. (2026). Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis. Human reproduction update, dmaf030. Advance online publication. https://doi.org/10.1093/humupd/dmaf030
5. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature reviews. Disease primers, 2, 16057. https://doi.org/10.1038/nrdp.2016.57
6. Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022). Polycystic ovary syndrome. The lancet. Diabetes & endocrinology, 10(9), 668–680. https://doi.org/10.1016/S2213-8587(22)00163-2
7. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology (2018). ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics and gynecology, 131(6), e157–e171. https://doi.org/10.1097/AOG.0000000000002656
8. Rosenfield, R. L., & Ehrmann, D. A. (2016). The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine reviews, 37(5), 467–520. https://doi.org/10.1210/er.2015-1104
9. Harada M. (2022). Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reproductive medicine and biology, 21(1), e12487. https://doi.org/10.1002/rmb2.12487
10. Louwers, Y. V., Visser, J. A., Dunaif, A., & Laven, J. S. E. (2025). POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Genetics of polycystic ovary syndrome (PCOS). Reproduction (Cambridge, England), 170(5), e250126. https://doi.org/10.1530/REP-25-0126
11. Patel S. (2018). Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. The Journal of steroid biochemistry and molecular biology, 182, 27–36. https://doi.org/10.1016/j.jsbmb.2018.04.008
12. Dapas, M., & Dunaif, A. (2022). Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. Endocrine reviews, 43(6), 927–965. https://doi.org/10.1210/endrev/bnac001
13. Bruni, V., Capozzi, A., & Lello, S. (2022). The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art. Reproductive sciences (Thousand Oaks, Calif.), 29(3), 668–679. https://doi.org/10.1007/s43032-021-00515-4
14. Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019). Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. Journal of the Endocrine Society, 3(8), 1545–1573. https://doi.org/10.1210/js.2019-00078
15. An, J., Zhou, Q., Guo, X., Xu, C., Jia, X., Cao, Z., & Lu, Q. (2025). From Pathophysiology to Treatment: The Role of Ferroptosis in PCOS. Frontiers in bioscience (Landmark edition), 30(2), 25586. https://doi.org/10.31083/FBL25586
16. Capozzi, A., Vignali, M., Scambia, G., & Lello, S. (2025). Pathophysiology and diagnostic criteria of PCOS. Minerva obstetrics and gynecology, 77(5), 361–372. https://doi.org/10.23736/S2724-606X.24.05612-4
17. Szeliga, A., Rudnicka, E., Maciejewska-Jeske, M., Kucharski, M., Kostrzak, A., Hajbos, M., Niwczyk, O., Smolarczyk, R., & Meczekalski, B. (2022). Neuroendocrine Determinants of Polycystic Ovary Syndrome. International journal of environmental research and public health, 19(5), 3089. https://doi.org/10.3390/ijerph19053089
18. Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023). Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. Journal of clinical medicine, 12(4), 1454. https://doi.org/10.3390/jcm12041454
19. Rutkowska, A. Z., & Diamanti-Kandarakis, E. (2016). Polycystic ovary syndrome and environmental toxins. Fertility and sterility, 106(4), 948–958. https://doi.org/10.1016/j.fertnstert.2016.08.031
20. Vatier, C., & Christin-Maitre, S. (2024). Epigenetic/circadian clocks and PCOS. Human reproduction (Oxford, England), 39(6), 1167–1175. https://doi.org/10.1093/humrep/deae066
21. Wekker, V., van Dammen, L., Koning, A., Heida, K. Y., Painter, R. C., Limpens, J., Laven, J. S. E., Roeters van Lennep, J. E., Roseboom, T. J., & Hoek, A. (2020). Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human reproduction update, 26(6), 942–960. https://doi.org/10.1093/humupd/dmaa029
22. Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
23. Ma, Y. C., Law, K. S., Wang, W. S., & Chang, H. M. (2025). Phenotypic variations in polycystic ovary syndrome: metabolic risks and emerging biomarkers. The Journal of endocrinology, 267(1), e250226. https://doi.org/10.1530/JOE-25-0226
24. Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and sterility, 106(1), 6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003
25. Panidis, D., Tziomalos, K., Misichronis, G., Papadakis, E., Betsas, G., Katsikis, I., & Macut, D. (2012). Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Human reproduction (Oxford, England), 27(2), 541–549. https://doi.org/10.1093/humrep/der418
26. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology (2018). ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics and gynecology, 131(6), e157–e171. https://doi.org/10.1097/AOG.0000000000002656
27. Williams, T., Moore, J. B., & Regehr, J. (2023). Polycystic Ovary Syndrome: Common Questions and Answers. American family physician, 107(3), 264–272.
28. Gasmi, A., Asghar, F., Zafar, S., Oliinyk, P., Khavrona, O., Lysiuk, R., Peana, M., Piscopo, S., Antonyak, H., Pen, J. J., Lozynska, I., Noor, S., Lenchyk, L., Muhammad, A., Vladimirova, I., Dub, N., Antoniv, O., Tsal, O., Upyr, T., & Bjørklund, G. (2024). Berberine: Pharmacological Features in Health, Disease and Aging. Current medicinal chemistry, 31(10), 1214–1234. https://doi.org/10.2174/0929867330666230207112539
29. Man, S., Potáček, M., Nečas, M., Žák, Z., & Dostál, J. (2001). Molecular and Crystal Structures of Three Berberine Derivatives. Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry, 6(5), 433–441. https://doi.org/10.3390/60500433
30. Sanlier, N., Ozler, E., & Karanfil, N. (2025). Potential Health Effects of the Natural Alkaloid Berberine: A Narrative Review. Nutrition reviews, nuaf192. Advance online publication. https://doi.org/10.1093/nutrit/nuaf192
31. Neag, M. A., Mocan, A., Echeverría, J., Pop, R. M., Bocsan, C. I., Crişan, G., & Buzoianu, A. D. (2018). Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Frontiers in pharmacology, 9, 557. https://doi.org/10.3389/fphar.2018.00557
32. Zhang, S. W., Zhou, J., Gober, H. J., Leung, W. T., & Wang, L. (2021). Effect and mechanism of berberine against polycystic ovary syndrome. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 138, 111468. https://doi.org/10.1016/j.biopha.2021.111468
33. Kuang, H., Duan, Y., Li, D., Xu, Y., Ai, W., Li, W., Wang, Y., Liu, S., Li, M., Liu, X., & Shao, M. (2020). The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. PloS one, 15(8), e0235404. https://doi.org/10.1371/journal.pone.0235404
34. Rondanelli, M., Riva, A., Petrangolini, G., Allegrini, P., Giacosa, A., Fazia, T., Bernardinelli, L., Gasparri, C., Peroni, G., & Perna, S. (2021). Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest–Post-Test Explanatory Study. Nutrients, 13(10), 3665. https://doi.org/10.3390/nu13103665
35. An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014). The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical endocrinology, 80(3), 425–431. https://doi.org/10.1111/cen.12294
36. Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., & Guan, Y. (2012). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology, 166(1), 99–105. https://doi.org/10.1530/EJE-11-0616
37. Zhang, N., Liu, X., Zhuang, L., Liu, X., Zhao, H., Shan, Y., Liu, Z., Li, F., Wang, Y., & Fang, J. (2020). Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regulatory toxicology and pharmacology : RTP, 110, 104544. https://doi.org/10.1016/j.yrtph.2019.104544
38. Wang, Z., Nie, K., Su, H., Tang, Y., Wang, H., Xu, X., & Dong, H. (2021). Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine : international journal of phytotherapy and phytopharmacology, 91, 153654. https://doi.org/10.1016/j.phymed.2021.153654
39. Spritzer, P. M., Marchesan, L. B., Santos, B. R., & Fighera, T. M. (2022). Hirsutism, Normal Androgens and Diagnosis of PCOS. Diagnostics, 12(8), 1922. https://doi.org/10.3390/diagnostics12081922
40. Xie, L., Zhang, D., Ma, H., He, H., Xia, Q., Shen, W., Chang, H., Deng, Y., Wu, Q., Cong, J., Wang, C. C., & Wu, X. (2019). The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evidence-based complementary and alternative medicine : eCAM, 2019, 7918631. https://doi.org/10.1155/2019/7918631
41. Qu, X., & Donnelly, R. (2020). Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. International journal of molecular sciences, 21(21), 8191. https://doi.org/10.3390/ijms21218191
42. Orio F, Muscogiuri G, Palomba S, et al. Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. e-SPEN Journal. 2013; 8(5): e200–e204,
doi:10.1016/j.clnme.2013.07.002
43. Mishra, N., Verma, R., & Jadaun, P. (2022). Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. Cureus, 14(1), e21781. https://doi.org/10.7759/cureus.21781
44. Xia, Q., Wang, W., Liu, Z., Xiao, J., Qiao, C., Zhao, Y., Li, B., Liu, Y., Peng, Y., Yang, X., Shi, J., Gao, X., & Wang, D. (2023). New insights into mechanisms of berberine in alleviating reproductive disorders of polycystic ovary syndrome: Anti-inflammatory properties. European journal of pharmacology, 939, 175433. https://doi.org/10.1016/j.ejphar.2022.175433
45. Shen, H. R., Xu, X., & Li, X. L. (2021). Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reproductive biology and endocrinology : RB&E, 19(1), 3. https://doi.org/10.1186/s12958-020-00684-y
46. García-Muñoz, A. M., Victoria-Montesinos, D., Ballester, P., Cerdá, B., & Zafrilla, P. (2024). A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin. Molecules (Basel, Switzerland), 29(19), 4576. https://doi.org/10.3390/molecules29194576
47. Hsu, Y. Y., Chen, C. S., Wu, S. N., Jong, Y. J., & Lo, Y. C. (2012). Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 46(5), 415–425. https://doi.org/10.1016/j.ejps.2012.03.004
48. Li, Z., Wang, Y., Xu, Q., Ma, J., Li, X., Yan, J., Tian, Y., Wen, Y., & Chen, T. (2023). Berberine and health outcomes: An umbrella review. Phytotherapy research : PTR, 37(5), 2051–2066. https://doi.org/10.1002/ptr.7806
49. Li, L., Li, C., Pan, P., Chen, X., Wu, X., Ng, E. H., & Yang, D. (2015). A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome. PloS one, 10(12), e0144072. https://doi.org/10.1371/journal.pone.0144072
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ewa Buczkowska, Aleksandra Marciszewska, Agnieszka Piechowicz, Natalia Popczyk, Agnieszka Przybyłowska, Jakub Jopek, Michał Popczyk, Sylwia Bryksy, Hanna Tymchenko, Jakub Kaźmierczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 101
Number of citations: 0
